Kytes positions itself as a project management software built for pharmaceutical realities—not generic project tracking. It supports regulatory execution, dossier readiness, country-wise launch ...
KBR (NYSE: KBR) announced that it has been awarded a new cost-plus-fixed-fee contract with a ceiling value of $149 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results